Oxytocin nasal spray ( DrugBank: Oxytocin )
2 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
72 | 下垂体性ADH分泌異常症 | 1 |
193 | プラダー・ウィリ症候群 | 1 |
72. 下垂体性ADH分泌異常症
臨床試験数 : 41 / 薬物数 : 27 - (DrugBank : 8) / 標的遺伝子数 : 7 - 標的パスウェイ数 : 10
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04789148 (ClinicalTrials.gov) | June 2023 | 5/3/2021 | Effects of Intranasal Oxytocin in Patients With Central Diabetes Insipidus | Effects of Intranasal Oxytocin in Patients With Central Diabetes Insipidus - A Pilot Study | Central Diabetes Insipidus | Drug: Oxytocin nasal spray | Elizabeth Austen Lawson | NULL | Not yet recruiting | 18 Years | 60 Years | All | 30 | Phase 1 | United States |
193. プラダー・ウィリ症候群
臨床試験数 : 113 / 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05298085 (ClinicalTrials.gov) | April 5, 2022 | 17/3/2022 | Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome | Effect of Intranasal Oxytocin on Dysphagia Related to Oropharyngo-oesophageal Dysmotility in Children and Adolescents With Prader-Willi Syndrome: a Phase 2B Study | Prader-Willi Syndrome | Drug: Oxytocin nasal spray;Drug: Placebo | University Hospital, Toulouse | NULL | Active, not recruiting | 2 Years | 17 Years | All | 25 | Phase 2/Phase 3 | France |